Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Treasury Shares (2019 - 2025)

Allogene Therapeutics' Treasury Shares history spans 7 years, with the latest figure at $1.8 million for Q3 2025.

  • For Q3 2025, Treasury Shares fell 26.23% year-over-year to $1.8 million; the TTM value through Sep 2025 reached $1.8 million, down 26.23%, while the annual FY2024 figure was $13.3 million, 9.55% up from the prior year.
  • Treasury Shares for Q3 2025 was $1.8 million at Allogene Therapeutics, down from $4.7 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $13.6 million in Q1 2024 and bottomed at $1.8 million in Q3 2025.
  • The 5-year median for Treasury Shares is $5.5 million (2022), against an average of $6.9 million.
  • The largest annual shift saw Treasury Shares soared 146.5% in 2023 before it plummeted 81.27% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $4.3 million in 2021, then grew by 28.92% to $5.5 million in 2022, then soared by 121.73% to $12.2 million in 2023, then increased by 9.55% to $13.3 million in 2024, then crashed by 86.54% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Treasury Shares are $1.8 million (Q3 2025), $4.7 million (Q2 2025), and $4.7 million (Q1 2025).